While the above-mentioned studies support our findings of p53-mediated miR107 induction with consecutive LRP1 downregulation and melanoma growth inhibition, it will be left for future studies to delineate the molecular mechanism of p53 induction by YO-2. The gene discussed is TP53; the disease is melanoma.